Analyst Consensus ?
ConsensusBuy59 ratings
Bullish3457.6%
Neutral2542.4%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Fiserv, Inc. · FISV · FY2026 Q1 · Calendar Q2 2026
Fiserv Q1 EPS Beats by 14% but Revenue Misses; Shares Drop 9.6%
Fiserv delivered a mixed Q1 2026: adjusted EPS of $1.79 topped estimates by 14%, aided by cost discipline and a lower 11% effective tax rate from a valuation allowance, while revenue of $4.68B fell 2.4% year-over-year and missed consensus by 1.1%. The market punished the revenue miss with a 9.6% abnormal decline and 2.9x normal volume, followed by an additional 3.8% drift lower. Management maintained full-year guidance for 1-3% organic revenue growth and mid-single-digit EPS expansion, citing second-half visibility and momentum in Clover VAS (up 18%), Finxact (70%+ account growth), and the AI-driven Project Elevate program. With the stock at $53.18 versus a $65.29 consensus target, investors are pricing in skepticism about near-term organic growth despite the EPS strength.
Reported Before market openNASDAQTechnology
$29.66B market cap
100quality score
Company context
Snapshot as of publicationFiserv, Inc. is a global provider of technology solutions for payments and financial services. Its operations are structured into three primary segments: Acceptance, Fintech, and Payments. The Acceptance segment enables businesses to process transactions at the point of sale and through digital channels, offering mobile payment capabilities and robust security and fraud prevention tools. Key offerings include Carat, its omnichannel commerce platform; Clover, a cloud-native platform for point-of-sale and business management; and Clover Connect, designed for independent software vendors. This segment reaches clients via diverse distribution channels, including direct sales, agent networks, ISVs, and financial institution partnerships.…
Earnings scorecard
Reported versus consensus
Reported EPS
$1.79
Consensus $2
EPS surprise
+14.0%
Reported versus consensus
Reported revenue
$4.67B
Consensus $4.73B
Revenue surprise
-1.1%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$53.68Current
$46Low
$130.01Average
$244High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Jul 24, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 22, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 22, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 10, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 9, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 9, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 8, 2026 |
| TD Cowen | Neutral | Neutral | Maintain | Jul 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 29, 2026 |
| UBS | Neutral | Neutral | Maintain | May 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | May 6, 2026 |
| Mizuho | Outperform | Outperform | Maintain | May 6, 2026 |
| Susquehanna | Positive | Positive | Maintain | May 4, 2026 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 26, 2026 |
| Tigress Financial | Buy | Buy | Maintain | Mar 11, 2026 |
| B. Riley Securities | Neutral | Neutral | Maintain | Feb 23, 2026 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Feb 11, 2026 |
| Seaport Global | Neutral | Buy | Downgrade | Oct 30, 2025 |
| Keybanc | Overweight | Downgrade | Oct 30, 2025 | |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Oct 30, 2025 |
| Bernstein | Market Perform | Outperform | Downgrade | Oct 30, 2025 |
| Argus Research | Hold | Buy | Downgrade | Oct 30, 2025 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Oct 29, 2025 |
| BTIG | Buy | Buy | Maintain | Oct 29, 2025 |
| Barclays | Overweight | Overweight | Maintain | Jul 28, 2025 |
| Baird | Outperform | Outperform | Maintain | Jul 24, 2025 |
| Jefferies | Hold | Hold | Maintain | May 27, 2025 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 26, 2023 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Oct 11, 2022 |
| Evercore ISI Group | Outperform | In Line | Upgrade | Aug 10, 2022 |
| Loop Capital | Buy | Buy | Maintain | May 3, 2022 |
| Rosenblatt | Buy | Buy | Maintain | Apr 27, 2022 |
| Cowen & Co. | Perform | Outperform | Downgrade | Apr 12, 2022 |
| Wedbush | Outperform | Outperform | Maintain | Dec 19, 2021 |
| B of A Securities | Buy | Buy | Maintain | Dec 16, 2021 |
| Edward Jones | Buy | Hold | Upgrade | Dec 15, 2021 |
| Exane BNP Paribas | Neutral | Underperform | Upgrade | Aug 9, 2021 |
| Compass Point | Buy | Buy | Maintain | Sep 17, 2020 |
| Oppenheimer | Perform | Outperform | Downgrade | Jun 28, 2020 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | May 8, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 7, 2020 |
| Deutsche Bank | Buy | Buy | Maintain | May 7, 2020 |
| CFRA | Buy | Buy | Maintain | May 7, 2020 |
| Canaccord Genuity | Buy | Buy | Maintain | Sep 12, 2019 |
| Berenberg | Buy | Buy | Maintain | Jul 31, 2019 |
| Tudor Pickering | Buy | Hold | Upgrade | Jul 2, 2019 |
| Northcoast Research | Buy | Neutral | Upgrade | Jun 25, 2019 |
| Northcoast | Buy | Neutral | Upgrade | Jun 25, 2019 |
| Buckingham | Buy | Buy | Maintain | Feb 7, 2019 |
| William Blair | Outperform | Market Perform | Upgrade | Jan 21, 2019 |
| Argus | Buy | Buy | Maintain | Sep 19, 2018 |
| Guggenheim | Buy | Neutral | Upgrade | Jul 16, 2017 |
| Pacific Crest | Equal Weight | Sector Weight | Maintain | Nov 18, 2016 |
| Monness Crespi Hardt | Buy | Neutral | Upgrade | Oct 4, 2016 |
| Monness, Crespi, Hardt | Buy | Neutral | Upgrade | Oct 3, 2016 |
| Sterne Agee CRT | Buy | Buy | Maintain | Dec 17, 2015 |
| FBR Capital | Market Perform | Outperform | Downgrade | Dec 5, 2014 |
| Sterne Agee | Buy | Neutral | Upgrade | Aug 6, 2013 |
| First Analysis | Overweight | Equal Weight | Upgrade | Aug 5, 2013 |
| DA Davidson | Neutral | Buy | Downgrade | May 1, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $53.68. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $52 | $49.97 | -3.1% | Jul 24, 2026 |
| BMO Capital | Andrew Bauch | $55 | $50.92 | +2.5% | Jul 22, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $53 | $50.61 | -1.3% | Jul 22, 2026 |
| Goldman Sachs | Will Nance | $60 | $50.6 | +11.8% | Jul 9, 2026 |
| Wells Fargo | Analyst unavailable | $56 | $50.6 | +4.3% | Jul 9, 2026 |
| Barclays | Nik Cremo | $58 | $52.71 | +8.0% | Jul 8, 2026 |
| BNP Paribas | Thomas Poutrieux | $46 | $56.23 | -14.3% | Jun 5, 2026 |
| Truist Financial | Matthew Coad | $58 | $57.02 | +8.0% | May 29, 2026 |
| Morgan Stanley | Analyst unavailable | $65 | $56.05 | +21.1% | May 29, 2026 |
| BMO Capital | Analyst unavailable | $60 | $53.46 | +11.8% | May 15, 2026 |
| UBS | Analyst unavailable | $65 | $55.79 | +21.1% | May 6, 2026 |
| RBC Capital | Analyst unavailable | $75 | $56.68 | +39.7% | May 6, 2026 |
| Mizuho Securities | Analyst unavailable | $90 | $57.28 | +67.7% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $78 | $57.28 | +45.3% | May 6, 2026 |
| Susquehanna | James Friedman | $91 | $62.14 | +69.5% | May 4, 2026 |
| Truist Financial | Analyst unavailable | $64 | $60.8 | +19.2% | Apr 24, 2026 |
| BMO Capital | Analyst unavailable | $65 | $63.26 | +21.1% | Apr 21, 2026 |
| Wells Fargo | Analyst unavailable | $62 | $53.9 | +15.5% | Mar 27, 2026 |
| Morgan Stanley | James Faucette | $64 | $62.85 | +19.2% | Feb 11, 2026 |
| UBS | Analyst unavailable | $70 | $62.92 | +30.4% | Feb 11, 2026 |
| Stephens | Charles Nabhan | $70 | $62.59 | +30.4% | Feb 11, 2026 |
| Cantor Fitzgerald | Ramsey El-Assal | $70 | $67.15 | +30.4% | Jan 26, 2026 |
| Stephens | Analyst unavailable | $75 | $66.46 | +39.7% | Jan 16, 2026 |
| Tigress Financial | Ivan Feinseth | $95 | $67.38 | +77.0% | Dec 31, 2025 |
| Mizuho Securities | Analyst unavailable | $100 | $67.94 | +86.3% | Dec 22, 2025 |
| Susquehanna | James Friedman | $99 | $64.26 | +84.4% | Nov 12, 2025 |
| Susquehanna | James Friedman | $99 | $63.8 | +84.4% | Nov 12, 2025 |
| BNP Paribas | Tom Poutrieux | $62 | $64.45 | +15.5% | Nov 5, 2025 |
| RBC Capital | Analyst unavailable | $85 | $68.29 | +58.3% | Oct 30, 2025 |
| UBS | Timothy Chiodo | $75 | $68.29 | +39.7% | Oct 30, 2025 |
| Oppenheimer | Rayna Kumar | $91 | $67.31 | +69.5% | Oct 30, 2025 |
| Stephens | Analyst unavailable | $80 | $70.6 | +49.0% | Oct 30, 2025 |
| Bernstein | Analyst unavailable | $80 | $70.6 | +49.0% | Oct 30, 2025 |
| Mizuho Securities | Analyst unavailable | $110 | $70.6 | +104.9% | Oct 30, 2025 |
| Morgan Stanley | James Faucette | $81 | $70.6 | +50.9% | Oct 30, 2025 |
| Goldman Sachs | Analyst unavailable | $79 | $70.6 | +47.2% | Oct 30, 2025 |
| Compass Point | Dominick Gabriele | $127.5 | $74.3 | +137.5% | Oct 29, 2025 |
| Mizuho Securities | Analyst unavailable | $145 | $127.83 | +170.1% | Oct 28, 2025 |
| Truist Financial | Analyst unavailable | $143 | $123.96 | +166.4% | Oct 24, 2025 |
| KeyBanc | Analyst unavailable | $145 | $126.07 | +170.1% | Oct 22, 2025 |
| Wells Fargo | Analyst unavailable | $130 | $126.07 | +142.2% | Oct 21, 2025 |
| BTIG | Analyst unavailable | $180 | $118 | +235.3% | Oct 17, 2025 |
| Deutsche Bank | Analyst unavailable | $122 | $121 | +127.3% | Oct 16, 2025 |
| Raymond James | Analyst unavailable | $167 | $125.96 | +211.1% | Oct 10, 2025 |
| Barclays | Ramsey El-Assal | $175 | $142.03 | +226.0% | Jul 28, 2025 |
| Morgan Stanley | Analyst unavailable | $500 | $172.33 | +831.4% | Jun 29, 2025 |
| Mizuho Securities | Dan Dolev | $200 | $159.13 | +272.6% | May 15, 2025 |
| RBC Capital | Analyst unavailable | $237 | $177.53 | +341.5% | Apr 25, 2025 |
| Morgan Stanley | Analyst unavailable | $268 | $177.53 | +399.3% | Apr 25, 2025 |
| UBS | Timothy Chiodo | $255 | $179.42 | +375.0% | Apr 25, 2025 |
| Piper Sandler | Analyst unavailable | $218 | $177.53 | +306.1% | Apr 25, 2025 |
| Seaport Global | Jeff Cantwell | $240 | $203.82 | +347.1% | Jan 14, 2025 |
| Stephens | Charles Nabhan | $255 | $201.76 | +375.0% | Dec 18, 2024 |
| Tigress Financial | Ivan Feinseth | $244 | $201.98 | +354.5% | Oct 29, 2024 |
| Mizuho Securities | Dan Dolev | $222 | $202.36 | +313.6% | Oct 24, 2024 |
| Argus Research | Stephen Biggar | $223 | $202.18 | +315.4% | Oct 23, 2024 |
| KeyBanc | Alex Markgraff | $225 | $199.67 | +319.2% | Oct 23, 2024 |
| RBC Capital | Kurt Hallead | $224 | $199.67 | +317.3% | Oct 23, 2024 |
| Wells Fargo | Andrew Bauch | $220 | $199.67 | +309.8% | Oct 23, 2024 |
| Williams Trading | Trevor Williams | $200 | $199.67 | +272.6% | Oct 22, 2024 |
| CFRA | Caydee Blankenship | $235 | $199.67 | +337.8% | Oct 22, 2024 |
| BTIG | Andrew Harte | $215 | $198.28 | +300.5% | Oct 22, 2024 |
| Williams Trading | Trevor Williams | $195 | $194.02 | +263.3% | Oct 16, 2024 |
| Morgan Stanley | James Faucette | $220 | $193.23 | +309.8% | Oct 15, 2024 |
| Bernstein | Harshita Rawat | $244 | $190.35 | +354.5% | Oct 14, 2024 |
| BMO Capital | Rufus Hone | $191 | $181.31 | +255.8% | Oct 1, 2024 |
| Citigroup | Ashwin Shirvaikar | $187 | $181.58 | +248.4% | Oct 1, 2024 |
| Oppenheimer | Rayna Kumar | $203 | $179.65 | +278.2% | Sep 30, 2024 |
| Robert W. Baird | David Koning | $200 | $177.61 | +272.6% | Sep 23, 2024 |
| BTIG | Andrew Harte | $200 | $170.17 | +272.6% | Aug 28, 2024 |
| Tigress Financial | Ivan Feinseth | $190 | $157.34 | +253.9% | Aug 6, 2024 |
| Mizuho Securities | Dan Dolev | $183 | $162.71 | +240.9% | Jul 30, 2024 |
| Deutsche Bank | Bryan Keane | $200 | $162.03 | +272.6% | Jul 25, 2024 |
| RBC Capital | Daniel Perlin | $183 | $161.16 | +240.9% | Jul 25, 2024 |
| B.Riley Financial | Hal Goetsch | $185 | $156.15 | +244.6% | Jul 25, 2024 |
| Argus Research | Stephen Biggar | $187 | $156.15 | +248.4% | Jul 25, 2024 |
| KeyBanc | Alex Markgraff | $180 | $161.16 | +235.3% | Jul 25, 2024 |
| Wells Fargo | Andrew Bauch | $190 | $161.16 | +253.9% | Jul 25, 2024 |
| Morgan Stanley | James Faucette | $175 | $114.23 | +226.0% | Jul 22, 2024 |
| Wells Fargo | Andrew Bauch | $180 | $148 | +235.3% | Jun 12, 2024 |
| Williams Trading | Trevor Williams | $160 | $156.78 | +198.1% | Mar 25, 2024 |
| Oppenheimer | Dominick Gabriele | $168 | $154.31 | +213.0% | Mar 19, 2024 |
| BNP Paribas | Tom Poutrieux | $156 | $135.4 | +190.6% | Jan 10, 2024 |
| KeyBanc | Alex Markgraff | $160 | $135.02 | +198.1% | Jan 8, 2024 |
| Wells Fargo | Analyst unavailable | $104 | $115.31 | +93.7% | Feb 8, 2023 |
| Credit Suisse | Analyst unavailable | $130 | $115.59 | +142.2% | Feb 8, 2023 |
| Susquehanna | Analyst unavailable | $140 | $115.48 | +160.8% | Feb 8, 2023 |
| Barclays | Analyst unavailable | $140 | $115.28 | +160.8% | Feb 8, 2023 |
| Raymond James | Analyst unavailable | $135 | $115.28 | +151.5% | Feb 8, 2023 |
| Wells Fargo | Analyst unavailable | $101 | $101.51 | +88.2% | Jan 9, 2023 |
| Goldman Sachs | Analyst unavailable | $105 | $100.73 | +95.6% | Jan 9, 2023 |
| Wells Fargo | Analyst unavailable | $107 | $105.75 | +99.3% | Sep 8, 2022 |
| Evercore ISI | David Togut | $149 | $108.11 | +177.6% | Aug 11, 2022 |
| Mizuho Securities | Dan Dolev | $145 | $106.08 | +170.1% | Aug 8, 2022 |
| Morgan Stanley | Analyst unavailable | $106 | $103.44 | +97.5% | Jul 27, 2022 |
| Wells Fargo | Jeff Cantwell | $97 | $91.72 | +80.7% | Jul 14, 2022 |
| Loop Capital Markets | Analyst unavailable | $125 | $99.5 | +132.9% | May 3, 2022 |
| Citigroup | Analyst unavailable | $122 | $102.18 | +127.3% | Apr 28, 2022 |
| Robert W. Baird | David Koning | $144 | $103.02 | +168.3% | Apr 20, 2022 |
| Citigroup | Ashwin Shirvaikar | $126 | $99.97 | +134.7% | Jan 26, 2022 |
| Mizuho Securities | Dan Dolev | $155 | $101.04 | +188.7% | Jan 25, 2022 |
| Tigress Financial | Ivan Feinseth | $150 | $109.11 | +179.4% | Jan 14, 2022 |
| Jefferies | Trevor Williams | $115 | $108.5 | +114.2% | Jan 12, 2022 |
| Wedbush | Moshe Katri | $130 | $100.52 | +142.2% | Dec 20, 2021 |
| Bank of America Securities | Jason Kupferberg | $139 | $103.65 | +158.9% | Dec 17, 2021 |
| Susquehanna | James Friedman | $135 | $104.23 | +151.5% | Dec 14, 2021 |
| UBS | Rayna Kumar | $108 | $100.88 | +101.2% | Nov 17, 2021 |
| Barclays | Ramsey El Assal | $128 | $98.49 | +138.5% | Oct 29, 2021 |
| Wolfe Research | Darrin Peller | $140 | $98.53 | +160.8% | Oct 28, 2021 |
Track every rating change on FISV the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
-8.8%
Event window
SPY move
+0.8%
Same window
Abnormal move
-9.6%
Stock minus SPY
Volume
2.9×
Versus trailing sessions
Subsequent drift
-3.8%
Up to 20 sessions
FISVSPY benchmark
Follow FISV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Adjusted EPS of $1.79 beat the $1.57 consensus by 14%, boosted partly by an 11% effective tax rate from a tax valuation allowance. Revenue of $4.68B declined 2.4% year-over-year and missed the $4.73B consensus by 1.1%. Clover VAS revenue grew 18%, accelerating from 12% Clover growth in Q4, with new verticals in healthcare and professional services. Finxact modern core platform posted 70%+ growth in accounts and positions. Management announced a stablecoin pilot for inter-bank money movement launching summer 2026. Project Elevate AI program identified hundreds of revenue-uplift and cost-reduction opportunities. Shares fell 9.6% on the report with 2.9x normal volume, then drifted an additional 3.8% lower.
Guidance delta
Management maintained full-year 2026 guidance for 1-3% organic revenue growth and mid-single-digit adjusted EPS expansion, unchanged from the prior quarter. Capex outlook remains stable. Guidance sentiment is maintained with confidence in clearer second-half visibility.
Key takeaways
- EPS beat of 14% was partly aided by a one-time tax valuation allowance lowering the effective rate to 11%, not solely operational improvement.
- Revenue decline of 2.4% reflects lapped non-recurring revenue comparisons and Argentina inflation and interest-rate headwinds.
- Clover VAS growth of 18% and Finxact 70%+ account growth are the strongest operational positives.
- AI-driven Project Elevate and stablecoin initiatives are forward-looking catalysts but not yet material to results.
- Disciplined capital allocation continues with $200M in share repurchases and a stable debt-to-EBITDA ratio.
Management priorities
- Execute the One Fiserv strategy with AI integration across client service, product development, and operations.
- Expand Clover into new verticals including healthcare and professional services, and international markets including Brazil and Canada.
- Launch a stablecoin pilot for inter-bank money movement in summer 2026.
- Drive Finxact modern core platform adoption and new API capabilities.
- Maintain disciplined capital allocation with share buybacks and stable leverage.
Related earnings events
TechnologySources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T15:11:43.021508+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T15:11:43.018623+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.